• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肾细胞癌的罕见转移途径：十二指肠受累及治疗挑战

Rare Metastatic Pathways of Renal Cell Carcinoma: Duodenal Involvement and Therapeutic Challenges.

作者信息

Peshin Supriya, Bashir Faizan, Moka Nagaishwarya

机构信息

Department of Internal Medicine Norton Community Hospital Virginia USA.

School of Medicine Shiraz University of Medical Sciences Shiraz Iran.

出版信息

Clin Case Rep. 2025 Jun 30;13(7):e70589. doi: 10.1002/ccr3.70589. eCollection 2025 Jul.

DOI:10.1002/ccr3.70589
PMID:40600205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12208906/
Abstract

Duodenal metastasis from renal cell carcinoma (RCC), though rare, warrants consideration in patients with unexplained gastrointestinal (GI) symptoms. Endoscopic evaluation and immunohistochemistry (IHC) are essential for accurate diagnosis, while molecular profiling helps identify mutations influencing disease behavior and treatment response. Systemic therapy with targeted agents and immunotherapy requires careful monitoring due to potential toxicity. A multidisciplinary approach remains essential for optimizing management and surveillance strategies in metastatic RCC.

摘要

肾细胞癌（RCC）的十二指肠转移虽然罕见，但对于有不明原因胃肠道（GI）症状的患者仍需考虑。内镜评估和免疫组织化学（IHC）对于准确诊断至关重要，而分子谱分析有助于识别影响疾病行为和治疗反应的突变。由于潜在毒性，使用靶向药物和免疫疗法进行全身治疗需要仔细监测。多学科方法对于优化转移性RCC的管理和监测策略仍然至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/73a0dc04a88b/CCR3-13-e70589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/3ea09f14ee64/CCR3-13-e70589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/b180786c5428/CCR3-13-e70589-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/73a0dc04a88b/CCR3-13-e70589-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/3ea09f14ee64/CCR3-13-e70589-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/b180786c5428/CCR3-13-e70589-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/732d/12208906/73a0dc04a88b/CCR3-13-e70589-g003.jpg

相似文献

1
Rare Metastatic Pathways of Renal Cell Carcinoma: Duodenal Involvement and Therapeutic Challenges.肾细胞癌的罕见转移途径：十二指肠受累及治疗挑战
Clin Case Rep. 2025 Jun 30;13(7):e70589. doi: 10.1002/ccr3.70589. eCollection 2025 Jul.
2
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.肾细胞癌患者中胰腺神经内分泌肿瘤与胰腺继发性病变的同步或异时表现。系统评价。
Semin Oncol. 2022 Dec;49(6):476-481. doi: 10.1053/j.seminoncol.2023.01.007. Epub 2023 Feb 2.
3
The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.颅外立体定向消融放疗治疗转移性肾细胞癌的新作用：系统评价。
Eur Urol Focus. 2023 Jan;9(1):114-124. doi: 10.1016/j.euf.2022.08.016. Epub 2022 Sep 20.
4
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.一线治疗成人晚期肾细胞癌：系统评价和网络荟萃分析。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理（2025年结石病专家共识）
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
Immunotherapy for metastatic renal cell carcinoma.转移性肾细胞癌的免疫治疗
Cochrane Database Syst Rev. 2017 May 15;5(5):CD011673. doi: 10.1002/14651858.CD011673.pub2.
7
Comparison of Partial Nephrectomy Versus Radical Nephrectomy for Metastatic Renal Cell Carcinoma in the Immunotherapy Era: A Propensity Score Matching, Population-Based Analysis.免疫治疗时代转移性肾细胞癌行部分肾切除术与根治性肾切除术的比较：一项倾向评分匹配的基于人群的分析
Ann Surg Oncol. 2025 Jun 19. doi: 10.1245/s10434-025-17642-w.
8
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.肾细胞癌治疗的当前临床实践指南：系统评价与批判性评估
Oncologist. 2017 Jun;22(6):667-679. doi: 10.1634/theoncologist.2016-0435. Epub 2017 Jun 7.
9
Hereditary Paraganglioma-Pheochromocytoma Syndromes遗传性副神经节瘤-嗜铬细胞瘤综合征
10
Pediatric Diffuse High-Grade Gliomas: A Comprehensive Review Of Ad-vanced Methods Of Diagnosis And Treatment.小儿弥漫性高级别胶质瘤：诊断与治疗先进方法的全面综述
Curr Cancer Drug Targets. 2025 Jun 30. doi: 10.2174/0115680096365252250618115641.

本文引用的文献

1
PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities.PAX8 在癌性和非肿瘤性组织中的表达：对来自 149 种不同肿瘤实体的 17000 多个肿瘤的组织微阵列研究。
Virchows Arch. 2024 Sep;485(3):491-507. doi: 10.1007/s00428-024-03872-y. Epub 2024 Aug 6.
2
Concomitant pancreatic and duodenal metastases 12 years after nephrectomy for renal cell carcinoma: a case report.肾细胞癌肾切除术后12年出现胰腺和十二指肠转移：一例报告
J Surg Case Rep. 2024 May 3;2024(5):rjae276. doi: 10.1093/jscr/rjae276. eCollection 2024 May.
3
Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.
肾细胞癌的胃肠道转移：一项回顾性多中心GETUG（泌尿生殖系统肿瘤研究组）研究。
Eur J Cancer. 2024 Mar;199:113534. doi: 10.1016/j.ejca.2024.113534. Epub 2024 Jan 15.
4
Evolution of cell therapy for renal cell carcinoma.细胞治疗肾细胞癌的进展。
Mol Cancer. 2024 Jan 9;23(1):8. doi: 10.1186/s12943-023-01911-x.
5
Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.免疫检查点抑制剂相关性胃炎的特征：来自一家主要的三级保健中心的报告。
Oncologist. 2023 Aug 3;28(8):706-713. doi: 10.1093/oncolo/oyad031.
6
Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?抗血管生成药物与免疫检查点抑制剂联合用于肾细胞癌：最佳选择？
Cancers (Basel). 2023 Feb 7;15(4):1048. doi: 10.3390/cancers15041048.
7
PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.PBRM1突变作为多种癌症免疫治疗的预测生物标志物。
Front Genet. 2023 Jan 9;13:1066347. doi: 10.3389/fgene.2022.1066347. eCollection 2022.
8
Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review.原发性肾细胞癌的胃肠道转移：单中心回顾
Front Oncol. 2021 Mar 23;11:644301. doi: 10.3389/fonc.2021.644301. eCollection 2021.
9
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.免疫检查点抑制剂与酪氨酸激酶抑制剂联合用于治疗肾细胞癌。
Expert Opin Biol Ther. 2021 Sep;21(9):1215-1226. doi: 10.1080/14712598.2021.1890713. Epub 2021 Feb 27.
10
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.阿昔替尼联合免疫检查点抑制剂：基于证据和专家共识的治疗优化及相关不良反应管理推荐。
Br J Cancer. 2020 Sep;123(6):898-904. doi: 10.1038/s41416-020-0949-9. Epub 2020 Jun 26.